Requires health insurers to cover colorectal cancer screenings for covered persons aged 33 or over and covered persons under the age of 33 if deemed medically necessary.
Summary
A4916 requires a broad set of New Jersey health coverage arrangements to pay for one colorectal cancer screening per year for covered persons age 33 or older, and for younger covered persons when a physician deems the screening medically necessary. The mandate applies across hospital service corporations, medical service corporations, health service corporations, individual and group health insurance policies, individual and small employer health benefits plans, HMO enrollee agreements, State Health Benefits Program contracts, School Employees’ Health Benefits Program contracts, and Medicaid, subject to federal approval where required.
The bill also removes cost sharing for a colonoscopy that follows a positive result on a non-colonoscopy colorectal cancer screening test. In the private insurance sections, the bill replaces prior language tied to United States Preventive Services Task Force recommendations with a fixed annual screening requirement and a physician-medical-necessity exception for younger patients. In Medicaid, the bill adds the same colorectal screening benefit to the list of covered services, again conditioned on federal financial participation and any needed federal approvals.
Impact
The bill would amend multiple sections of New Jersey insurance and Medicaid law to create a uniform colorectal cancer screening benefit across most major coverage types in the state. It changes the existing preventive-care framework by specifying an annual screening entitlement beginning at age 33, rather than relying on screening frequency and method under USPSTF recommendations, and it bars deductibles, coinsurance, copayments, or other cost sharing for follow-up colonoscopies after a positive non-colonoscopy screening test. For Medicaid, the bill adds colorectal screening to the covered services list, but only to the extent permitted by federal law and with federal financial participation.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal legislative support/opposition in the available context. Based on the bill text, the measure appears strongly pro-screening and preventive-care oriented, with a public-health rationale aimed at earlier detection of colorectal cancer and reduced financial barriers to follow-up care. The overall framing is consumer- and patient-protective, and the sponsor statement presents the bill as a coverage expansion rather than a restriction.
Contention
The main policy issue likely to draw scrutiny is the age threshold of 33, which is much younger than typical colorectal screening benchmarks and could raise questions about medical justification, utilization, and premium or program-cost impacts. Another likely point of contention is the bill’s move away from flexible USPSTF-based screening standards toward a fixed annual mandate, which may concern insurers and administrators who prefer clinical guideline-based coverage rules. For Medicaid, the federal-approval and federal-financial-participation conditions could also be a practical issue, since implementation depends on whether the screening benefit can be matched with federal funding and compliance requirements.
Same As
Requires health insurers to cover colorectal cancer screenings for covered persons aged 33 or over and covered persons under the age of 33 if deemed medically necessary.